Frontiers in Oncology (Mar 2023)

Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study

  • Luis Gabriel Parra-Lara,
  • Luis Gabriel Parra-Lara,
  • Juan Camilo Falla-Martínez,
  • Daniel Francisco Isaza-Pierotti,
  • Diana Marcela Mendoza-Urbano,
  • Andrés R. Tangua-Arias,
  • Juan Carlos Bravo,
  • Luis Eduardo Bravo,
  • Ángela R. Zambrano

DOI
https://doi.org/10.3389/fonc.2023.1069369
Journal volume & issue
Vol. 13

Abstract

Read online

BackgroundGastric adenocarcinoma (GA) has changed in recent decades. Cancer estimates are often calculated from population-based cancer registries, which lack valuable information to guide decision-making (clinical outcomes). We describe the trends in clinical practice for GA using a hospital-based cancer registry over a timespan of 15 years.MethodsA retrospective cohort study was conducted. Data were gathered from adults diagnosed and treated for GA at Fundación Valle del Lili (FVL), between 2000 and 2014, from the hospital’s own cancer registry and crossed with Cali’s Cancer Registry. Additional data were obtained directly from clinical records, pathology reports and the clinical laboratory. Patients younger than 18 years and those for whom limited information was available in the medical history were excluded. A survival analysis was conducted using Kaplan-Meier method.ResultsA total of 500 patients met eligibility criteria. Median age was 64 years (IQR: 54-74 years), 39.8% were female, 22.2% were at an early stage, 32.2% had a locally advanced disease, and 29% a metastatic disease, 69% had intestinal subtype, 48.6% had a positive H. pylori test, 85.2% had a distal lesion, 62% underwent gastrectomy, 60.6% lymphadenectomy, and 40.6% received chemotherapy. Survival at 5 years for all cases was 39.9% (CI 95% 35.3-44.5). Survival decreased over time in all groups and was lower in age-groups <39 and 60-79 with either locally advanced or metastatic disease. Prognostic factors that were significant in the Cox proportional-hazards model were late stages of the tumor (locally advanced: HR=2.52; metastatic: HR=4.17), diffuse subtype (HR=1.40), gastrectomy (subtotal: HR=0.42; total: 0.44) and palliative chemotherapy (HR=0.61).ConclusionsThe treatment of GA has changed in recent decades. GA survival was associated with clinical staging, diffuse subtype, gastrectomy and palliative chemotherapy. These findings must be interpreted in the context of a hospital-based study.

Keywords